STORM is presenting at #ISMB2024, the world's largest conference focused on #bioinformatics and #computationalbiology! 📢 Presentation details: D-326: R toolkit for biomarker discovery, Track: TransMed 📅 Date, time & location: 16th July, 12:20-14:20 EDT - Montreal, Canada

Thank you to @Drughuntersite for following our story. This piece offers an excellent update on #METTL3, sharing the exciting journey of #STC15 and the progression of our lead asset. We’re eager to continue and share our progress with you all! #ASCO2024 #RNA #drugdevelopment

#STORM is featured in Medical Technology & Medical Device Network 'ASCO 2024 unveils practice - changing research in oncology' article! CEO, Jerry McMahon discusses the advances and current therapies presented at ASCO 2024. Read the full article here: bit.ly/3WwARjS.

Great to see #STORMTherapeutics featured in Labiotech.eu's summary of 'Six epigenetics companies making strides in 2024.' Read about our interim Phase I clinical data on lead candidate #STC15, targeting solid tumors, here bit.ly/4c7PPBC

Great to see STORM's CEO, Jerry McMahon, featured in Citeline's discussion on advancements in #oncology and the use of technology in the evolving landscape of drug development. 💡 An insightful discussion amongst experts from #ASCO2024! Read here: bit.ly/3AE1x9S

#STORM's Senior Vice President Therapeutics, Matthew Fyfe, is chairing a session at the International Symposium on Medicinal Chemistry! 📢 Title: Session 4 'Chemical Biology': Targeting RNA and RNA-Regulatory Proteins 🕐 Date & Time: 2nd September, 13:45 CEST 📍 Rome, Italy

Our CEO, Jerry McMahon, provides insight into the potential of STORM's lead product STC-15 "across multiple therapeutic areas" in Drug Discovery World's article which delves into the new mechanisms of action, receptors and modalities in cancer immunotherapy, here: bit.ly/3Zxmy0s

Meet the #STORM team at @ELRIG_UK Drug Discovery 2024 on the 📅2-3 October at the 📍ExCel in London, where will be presenting the poster, 'Working towards pandemic preparedness: Inhibiting viral 5' RNA cap methylation with potent, selective, broad-spectrum small molecules'.

Thanks to Cambridge University for spotlighting us as one of '10 Cambridge spinouts changing the story of cancer'! Check out STORM in the article 👇 and discover how we are pioneering cellular reprogramming through RNA modifications to treat disease🧬#lifesciences #biotech #cancer

STORM is in Barcelona for the EORTC-NCI-AACR (#ENA) Symposium! Poster details below 👇 📢 Session Title: New therapies in immuno oncology 📅 Session Date and Time: 25 October, 09:00 - 15:00 CEST 🏢 Location: Exhibition Hall 📌 Catalog Number: 451 🗞️ Presentation Number: PB439

Visit our poster presentation at #SITC2024! 📝 Title: Phase 1 dose escalation and cohort expansion study evaluating safety, PK, PD and clinical activity of STC-15, a METTL3 inhibitor, in patients with advanced malignancies 📅 Date: Saturday 9 November 📌 Abstract number: 676

Check out the latest insights from our CEO, Jerry McMahon, featured in an article by International Clinical Trials discussing the current field of Alzheimer’s disease, drugs, biomarkers, and the future of treatment options for #neurogenerativediseases: bit.ly/3YJimc7

Our Group Leader, Molecular Cell Biology, Alexandra Sapetschnig, is presenting at RNA Modifications and Epitranscriptomics on 15 November from 11:20-11:40 CET! Come along to hear about #STORM's first-in-class #METTL3 inhibitor #STC15 and new #clinical data presented at #SITC2024.

Look out for the #STORM team at London Life Sciences Week! Our CEO, Jerry McMahon, will attend the upcoming Jefferies London Healthcare Conference from 19-21 November alongside our CBO, Marguerite Hutchinson.

Clinical milestone achieved & CMO appointed! The #firstpatient has been dosed in our collaboration with Coherus Biosciences, commencing a Phase 1b/2 study with STC-15 in combination with Coherus’s next generation PD-1 inhibitor, LOQTORZI® (toripalimab). bit.ly/3Z5nlVv

📣 Appointment news from STORM! We're excited to welcome veteran cancer drug developer Eric Martin as Chief Development Officer as we advance our METTL3 inhibitor STC-15 through Phase 1b/2 development.🔗 Learn more: bit.ly/44yokjU #oncology #biotech #drugdevelopment